Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Group 1 - Kodiak Sciences is experiencing a surge in stock price, with shares up 13.68% at $45.20, reaching a new 52-week high [4] - The company is highlighting the safety profile of its drug Zenkuda, reporting no cases of intraocular inflammation and a low rate of cataract adverse events [3] - Kodiak intends to accelerate the submission timeline for a biologics license application (BLA) for Zenkuda, indicating a multi-indication BLA-ready profile [3] Group 2 - In the GLOW2 study, 62.5% of patients treated with Zenkuda achieved at least a two-step improvement in Diabetic Retinopathy Severity Scale (DRSS) scores, compared to only 3.3% in the sham group [2] - The positive data from the GLOW2 study is contributing to investor confidence and the potential for a faster path toward BLA [1]